GlassScriptPhysician profile
Jeffrey Mincher
NPI 1639518525
$2,125.05
in general payments reported to CMS, 2019-2025
24 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.86 · 2021: $220 · 2022: $699 · 2023: $634 · 2024: $330 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.28 | 2021-2025 | |
| Novo Nordisk INC | $360.61 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $190.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $138.57 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.65 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.71 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.73 | 2022-2024 | Airsupra, Breztri |
| Amgen INC. | $58.24 | 2022-2025 | Evenity, Prolia |
| Daiichi Sankyo INC. | $57.62 | 2021-2024 | Injectafer |
| Amarin Pharma, INC. | $48.83 | 2020-2022 | |
| Sanofi Pasteur INC. | $47.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.93 | 2024 | |
| Hologic Sales and Service, LLC | $35.89 | 2023-2024 | Aptima, Thinprep 2000 Processor, Third Wave |
| Otsuka America Pharmaceutical, INC. | $31.80 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $30.33 | 2023-2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $27.21 | 2024 | |
| Glaxosmithkline, LLC. | $26.27 | 2022-2023 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $17.90 | 2021 | |
| Teleflex LLC | $16.83 | 2025 | Barrigel |
| Eisai INC. | $15.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2023 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $14.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mincher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.